ACE2 and lung carcinoma: Importantly, Feng et al. reported that cisplatin and gemcitabine significantly upregulate ACE2 expression in A549 NSCLC cancer cells, indicating that standard of care (SOC) therapy can affect ACE2 expression levels in lung cancer cells in vitro [11].